The global bioprinting market sits at a compelling intersection of biology, materials science, and precision manufacturing. Demand is rising across pharmaceutical research, regenerative medicine, and organ transplantation as bioprinted tissue constructs prove their value as alternatives to animal models and donor tissues. Legislative pressure on animal testing in cosmetics, a persistent organ donor shortage, and the growing cost burden of clinical drug development are all accelerating adoption. At the same time, advances in bioink formulations, AI-assisted process control, and new printer hardware are steadily expanding what is technically achievable.